Physiologically based pharmacokinetic modeling in drug discovery and development: A pharmaceutical industry perspective

Jones, HM, Chen, Y, Gibson, C, Heimbach, T, Parrott, N, Peters, SA, Snoeys, J, Upreti, VV +2 more·2015·Clinical Pharmacology & Therapeutics
DOI 10.1002/cpt.37

Cited by (487)

Items 101–200 of 487

  1. Physiologically Based Pharmacokinetic Modeling of Therapeutic Proteins
    Harvey Wong, Timothy W. Chow · 2017 · Journal of Pharmaceutical Sciences
  2. Beyond AOPs: A Mechanistic Evaluation of NAMs in DART Testing
    Ramya Rajagopal, Maria Teresa Baltazar, Paul Lawford Carmichael, Matthew Philip Dent, Julia Head, Hequn Li, Iris I. Müller, Joe Reynolds, Kritika Sadh, Wendy Simpson et al. · 2022 · Frontiers in Toxicology
  3. In Silico Studies to Support Vaccine Development
    Leonor Saldanha, Ülo Langel, Nuno Vale · 2023 · Pharmaceutics
  4. Scientific Rationale for Designing Controlled Drug Delivery Systems
    Anu Hardenia, Neha Maheshwari, Shiv Shankar Hardenia, Sunil Kumar Dwivedi, Rahul Maheshwari, Rakesh Kumar Tekade · 2019 · Elsevier eBooks
  5. Prediction of drug‐drug interactions using physiologically‐based pharmacokinetic models of CYP450 modulators included in Simcyp software
    Niloufar Marsousi, Jules Alexandre Desmeules, Serge L. Rudaz, Youssef Daali · 2017 · Biopharmaceutics & Drug Disposition
  6. Current use and future potential of (physiologically based) pharmacokinetic modelling of radiopharmaceuticals: a review
    Hinke Siebinga, Berlinda J. de Wit–van der Veen, Marcel P. M. Stokkel, Alwin D. R. Huitema, Jeroen J. M. A. Hendrikx · 2022 · Theranostics
  7. Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation
    Daniel Scotcher, Christopher R. Jones, Maria M. Posada, Aleksandra Galetin, Amin Rostami‐Hodjegan · 2016 · The AAPS Journal
  8. Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug–Drug and Drug–Disease Interactions
    Chiho Ono, Poe‐Hirr Hsyu, Richat Abbas, Cho‐Ming Loi, Shinji Yamazaki · 2017 · Drug Metabolism and Disposition
  9. PBPK in Preterm and Term Neonates: A Review
    Robin Michelet, Jan Van Bocxlaer, An Vermeulen · 2017 · Current Pharmaceutical Design
  10. PBPK Absorption Modeling of Food Effect and Bioequivalence in Fed State for Two Formulations with Crystalline and Amorphous Forms of BCS 2 Class Drug in Generic Drug Development
    Rebeka Jereb, Jerneja Opara, Igor Legen, Boštjan Petek, Aleksander Bajc, Simon Žakelj, Albin Kristl · 2019 · AAPS PharmSciTech
  11. The Promise of Long-Acting Antiretroviral Therapies: From Need to Manufacture
    Howard Eliot Gendelman, JoEllyn McMillan, Aditya N. Bade, Benson Edagwa, Bhavesh D. Kevadiya · 2019 · Trends in Microbiology
  12. A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization
    Yu Yuan, Lu-Lu Yu, Chenghao Bi, Liping Huang, Buda Su, Jiaxuan Nie, Zhiying Dou, Shenshen Yang, Yubo Li · 2025 · Chinese Medicine
  13. Physiologically Based Pharmacokinetic Modeling to Identify Physiological and Molecular Characteristics Driving Variability in Drug Exposure
    Andrew Rowland, Madelé van Dyk, Ashley Mark Hopkins, Reham Mounzer, Thomas M. Polasek, Amin Rostami‐Hodjegan, Michael Joseph Sorich · 2018 · Clinical Pharmacology & Therapeutics
  14. Development of best practices in physiologically based pharmacokinetic modeling to support clinical pharmacology regulatory decision‐making—A workshop summary
    Daphney Jean, Kunal Naik, Lauren Milligan, Stephen David Hall, Shiew Mei Huang, Nina Isoherranen, Colleen Kuemmel, Paul Seo, Million A. Tegenge, Yaning Wang et al. · 2021 · CPT Pharmacometrics & Systems Pharmacology
  15. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products – a PEARRL review
    Mariana Guimarães, Marina Statelova, René Holm, Christos I. Reppas, Moira Symillides, Maria Vertzoni, Nikoletta Fotaki · 2018 · Journal of Pharmacy and Pharmacology
  16. Physiologically Based Pharmacokinetics of Dexamethasone in Rats
    Dawei Song, Le Sun, Debra C. DuBois, Richard R. Almon, Shengnan Meng, William J. Jusko · 2020 · Drug Metabolism and Disposition
  17. Physiologically based pharmacokinetic (PBPK) modeling for prediction of celecoxib pharmacokinetics according to CYP2C9 genetic polymorphism
    Young‐Hoon Kim, Pureum Kang, Chang‐Keun Cho, Eui Hyun Jung, Hye‐Jeong Park, Yun Jeong Lee, Jung‐Woo Bae, Choon‐Gon Jang, Seok‐Yong Lee · 2021 · Archives of Pharmacal Research
  18. Incorporation of Lysosomal Sequestration in the Mechanistic Model for Prediction of Tissue Distribution of Basic Drugs
    Assmus, Frauke, Houston, J. Brian, Galetin, Aleksandra · 2017 · European Journal of Pharmaceutical Sciences
  19. Transporter‐Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models
    Manthena V. S. Varma, Ayman F. El‐Kattan · 2016 · The Journal of Clinical Pharmacology
  20. Digital twin-enhanced three-organ microphysiological system for studying drug pharmacokinetics in pregnant women
    Katja Graf, Jose Martin Murrieta-Coxca, Tobias Vogt, Sophie Besser, Daria Geilen, Tim Kaden, Anne-Katrin Bothe, Diana Maria Morales Prieto, Behnam Amiri, Stephan Schaller et al. · 2025 · Frontiers in Pharmacology
  21. Translational PK/PD modeling to increase probability of success in drug discovery and early development
    Thierry Lavé, Antonello Caruso, Neil John Parrott, Antje‐Christine Walz · 2016 · Drug Discovery Today Technologies
  22. Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism
    Yukina Fukuchi, Kota Toshimoto, Takanori Mori, Keisuke Kakimoto, Yoshifusa Tobe, Takeshi Sawada, Ryuta Asaumi, Takeyuki Iwata, Yoshitaka Hashimoto, Ken‐ichi Nunoya et al. · 2017 · Journal of Pharmaceutical Sciences
  23. Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug‐Drug Interaction Potential
    Stefan Willmann, Katrin Coboeken, Stefanie Kapsa, Kirstin Thelen, Markus Mundhenke, Kerstin Fischer, Burkhard J. Hügl, Wolfgang M. Mück · 2020 · The Journal of Clinical Pharmacology
  24. A review of pregnancy-induced changes in opioid pharmacokinetics, placental transfer, and fetal exposure: Towards fetomaternal physiologically-based pharmacokinetic modeling to improve the treatment of neonatal opioid withdrawal syndrome
    Matthijs W. van Hoogdalem, Scott L. Wexelblatt, Henry T. Akinbi, Alexander A. T. M. M. Vinks, Tomoyuki Mizuno · 2021 · Pharmacology & Therapeutics
  25. Establishment of a clinically relevant specification for dissolution testing using physiologically based pharmacokinetic (PBPK) modeling approaches
    Takafumi Kato, Hiroshi Nakagawa, Tsuyoshi Mikkaichi, Takuya Miyano, Yoshiaki Matsumoto, Shuichi Ando · 2020 · European Journal of Pharmaceutics and Biopharmaceutics
  26. Physiologically Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) as a Victim and Perpetrator of Drug-Drug Interactions
    Heidi J. Einolf, Wen Lin, Christina S. Won, Lai Wang, Helen Gu, Dung Yu Chun, Handan He, James B. Mangold · 2017 · Drug Metabolism and Disposition
  27. Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development
    Nathalie Rioux, Nigel J. Waters · 2016 · Drug Metabolism and Disposition
  28. Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction
    Aleksandra Galetin, Ping Zhao, Shiew Mei Huang · 2017 · Journal of Pharmaceutical Sciences
  29. PBPK Modeling Strategy for Predicting Complex Drug Interactions of Letermovir as a Perpetrator in Support of Product Labeling
    Ying‐Hong Wang, Dapeng Chen, Georgy Hartmann, Carolyn R. Cho, Karsten Menzel · 2018 · Clinical Pharmacology & Therapeutics
  30. The Evolution and Future Directions of PBPK Modeling in FDA Regulatory Review
    Yangkexin Li, Henry Sun, Zuoli Zhang · 2025 · Pharmaceutics
  31. Physiologically Based Pharmacokinetic Model of the CYP2D6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions
    Weize Huang, Mariko Nakano, Jennifer E. Sager, Isabelle Ragueneau, Nina Isoherranen · 2017 · Drug Metabolism and Disposition
  32. Quantitative mass spectrometry-based proteomics in the era of model-informed drug development: Applications in translational pharmacology and recommendations for best practice
    Eman El‐Khateeb, Areti‐Maria Vasilogianni, Sarah Alrubia, Zubida M. Al‐Majdoub, Narciso A. S. Couto, Martyn Howard, Jill Barber, Amin Rostami‐Hodjegan, Brahim Achour · 2019 · Pharmacology & Therapeutics
  33. Physiologically based and population PK modeling in optimizing drug development: A predict–learn–confirm analysis
    Ajit Suri, Sunny Hong Chapel, C. Lu, Karthik Venkatakrishnan · 2015 · Clinical Pharmacology & Therapeutics
  34. Development of a Novel Simplified PBPK Absorption Model to Explain the Higher Relative Bioavailability of the OROS® Formulation of Oxybutynin
    Andrés Olivares‐Morales, Avijit Ghosh, Leon J Aarons, Amin Rostami‐Hodjegan · 2016 · The AAPS Journal
  35. The Constraints, Construction, and Verification of a Strain-Specific Physiologically Based Pharmacokinetic Rat Model
    Helen Musther, Matthew D. Harwood, Jiansong Yang, David B. Turner, Amin Rostami‐Hodjegan, Masoud Jamei · 2017 · Journal of Pharmaceutical Sciences
  36. Model‐Based Assessments of CYP‐Mediated Drug–Drug Interaction Risk of Alectinib: Physiologically Based Pharmacokinetic Modeling Supported Clinical Development
    Yumi Cleary, Michael Gertz, Peter N. Morcos, Li J. Yu, Kuresh A. Youdim, Alex Phipps, Stephen M. Fowler, Neil John Parrott · 2017 · Clinical Pharmacology & Therapeutics
  37. Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use
    Fiona R. Sewell, Kathryn L. Chapman, Jessica A. Couch, Maggie Dempster, Shawn M. Heidel, Lise I. Loberg, Curtis C. Maier, Timothy K. MacLachlan, Marque D. Todd, Jan Willem van der Laan · 2017 · mAbs
  38. Robust PBPK/PD-Based Model Predictive Control of Blood Glucose
    Stephan Schaller, Jörg Lippert, Lukas A. Schaupp, Thomas Rudolf Pieber, Andreas Schuppert, Thomas Eißing · 2015 · IEEE Transactions on Biomedical Engineering
  39. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions
    Luna Prieto Garcia, David L. I. Janzén, Kajsa P. Kanebratt, Hans Ericsson, Hans Lennernäs, Anna Lundahl · 2018 · Drug Metabolism and Disposition
  40. Assessing the potential of solid dispersions to improve dissolution rate and bioavailability of valsartan: In vitro-in silico approach
    Djordje P. Medarević, Sandra Cvijić, Vladimir Dobričić, Miodrag N. Mitrić, Jelena Djuriš, Svetlana R. Ibric · 2018 · European Journal of Pharmaceutical Sciences
  41. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of In Vivo Clinical Studies: Current Status, Challenges, and Opportunities
    Ioannis Loisios-Konstantinidis, Jennifer Dressman · 2020 · Molecular Pharmaceutics
  42. Opportunities to Apply the 3Rs in Safety Assessment Programs
    Fiona R. Sewell, Joanna Edwards, Helen M. Prior, Sally Robinson · 2016 · ILAR Journal
  43. Physiologically based pharmacokinetic modeling of small molecules: How much progress have we made?
    Nina Isoherranen · 2024 · Drug Metabolism and Disposition
  44. DigiLoCS: A leap forward in predictive organ-on-chip simulations
    Manoja Rajalakshmi Aravindakshan, Chittaranjan Mandal, Alex Pothen, Stephan Schaller, Christian Maaß · 2025 · PLoS ONE
  45. Investigating Oral Absorption of Carbamazepine in Pediatric Populations
    Philip Kohlmann, Cordula Stillhart, Martin Kuentz, Neil John Parrott · 2017 · The AAPS Journal
  46. Global Sensitivity Analysis of the Rodgers and Rowland Model for Prediction of Tissue: Plasma Partitioning Coefficients: Assessment of the Key Physiological and Physicochemical Factors That Determine Small-Molecule Tissue Distribution
    Estelle Yau, Andrés Olivares‐Morales, Michael Gertz, Neil John Parrott, Adam S. Darwich, Leon J Aarons, Kayode Ogungbenro · 2020 · The AAPS Journal
  47. Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologically Based Models? A Feasibility Study Based on 12 Development Compounds
    Neil John Parrott, Nenad Manevski, Andrés Olivares‐Morales · 2022 · Molecular Pharmaceutics
  48. Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics (Review)
    Ioannis S. Vizirianakis, George A. Mystridis, Konstantinos Avgoustakis, Dimitrios G. Fatouros, Marios Spanakis · 2016 · Oncology Reports
  49. Recent Progress on Physiologically Based Pharmacokinetic (PBPK) Model: A Review Based on Bibliometrics
    Huang He, Wenjing Zhao, Ning Qin, Xiaoli Duan · 2024 · Toxics
  50. In Silico Modeling of the Antiplatelet Pharmacodynamics of Low‐dose Aspirin in Health and Disease
    Alberto Giaretta, Bianca Rocca, Barbara Di Camillo, G.M. Toffolo, Carlo Patrono · 2017 · Clinical Pharmacology & Therapeutics
  51. An in vitro - in silico approach for the formulation and characterization of ranitidine gastroretentive delivery systems
    Sandra Cvijić, Svetlana R. Ibric, Jelena Parojčić, Jelena Djuriš · 2018 · Journal of Drug Delivery Science and Technology
  52. Computational Methods to Predict Toxicity
    M Cronin, Miyoung Yoon · 2018 · Elsevier eBooks
  53. Perspectives from the Innovation and Quality Consortium Induction Working Group on Factors Impacting Clinical Drug-Drug Interactions Resulting from Induction: Focus on Cytochrome 3A Substrates
    Diane Ramsden, Conrad A. Fung, Niresh Hariparsad, Jane R. Kenny, Michael A. Mohutsky, Neil John Parrott, Sarah M. C. Robertson, Donald Tweedie · 2019 · Drug Metabolism and Disposition
  54. Physiologically‐based pharmacokinetic model for alectinib, ruxolitinib, and panobinostat in the presence of cancer, renal impairment, and hepatic impairment
    Mo’tasem M. Alsmadi, Nour Aldaoud, Mays M. Jaradat, Saja B. Alzughoul, Amani D. Abu Kwiak, Salam Abu Laila, Ayat J. Abu Shameh, Mohammad K. Alhazabreh, Sana’a A. Jaber, Hala T. Abu Kassab · 2021 · Biopharmaceutics & Drug Disposition
  55. The Development of an In Vitro Horizontal Diffusion Cell to Monitor Nasal Powder Penetration Inline
    Péter Gieszinger, T. Kiss, Piroska Szabó‐Révész, Rita Ambrus · 2021 · Pharmaceutics
  56. Tissue expression profile of human neonatal Fc receptor (FcRn) in Tg32 transgenic mice
    Yao‐Yun Fan, Lindsay B. Avery, Mengmeng Wang, Denise M. O’Hara, Sheldon S. Leung, Hendrik Neubert · 2016 · mAbs
  57. In vitro/in silicoapproach in the development of simvastatin-loaded self-microemulsifying drug delivery systems
    Zora Ćetković, Sandra Cvijić, Dragana Vasiljević · 2017 · Drug Development and Industrial Pharmacy
  58. Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling – A case study of doxorubicin with dose metrics considerations
    Hequn Li, Haitao Yuan, A. Middleton, Jin Li, Beate Nicol, Paul Lawford Carmichael, Jiabin Guo, Shuangqing Peng, Qiang Zhang · 2021 · Toxicology in Vitro
  59. Design and conduct considerations for studies in patients with impaired renal function
    Paulien G. M. Ravenstijn, Manoranjenni Chetty, Pooja Manchandani · 2021 · Clinical and Translational Science
  60. Design and conduct considerations for studies in patients with hepatic impairment
    Paulien G. M. Ravenstijn, Manoranjenni Chetty, Pooja Manchandani, Mohamed A. Elmeliegy, Hisham Qosa, Islam Rasem Younis · 2022 · Clinical and Translational Science
  61. Toward Optimum Benefit‐Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles
    Karthik Venkatakrishnan, C Burgess, Neeraj Gupta, Ajit Suri, T Takubo, Xiaofei Zhou, D DeMuria, Manfred Lehnert, K Takeyama, Saurav P. Singhvi et al. · 2016 · Clinical and Translational Science
  62. In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
    Yi Jin, Hubert Borell, Anne Gardin, Mike Ufer, Felix Huth, Gian Camenisch · 2017 · European Journal of Clinical Pharmacology
  63. Process and System Clearances in Pharmacokinetic Models: Our Basic Clearance Concepts Are Correct
    Ken Korzekwa, Swati Nagar · 2023 · Drug Metabolism and Disposition
  64. Physiologically based modeling of LNP-mediated delivery of mRNA in the vascular system
    Hamideh Parhiz, Vladimir V. Shuvaev, Qin Li, Tyler Ellis Papp, Awurama Akyianu, Ruiqi Shi, Amir Yadegari, Hamna Shahnawaz, Sean C. Semple, Barbara L. Mui et al. · 2024 · Molecular Therapy — Nucleic Acids
  65. In vitro - in vivo - in silico approach in the development of inhaled drug products: Nanocrystal-based formulations with budesonide as a model drug
    Changzhi Shi, Jelisaveta Ignjatović, Tingting Liu, Meihua Han, Dongmei Cun, Jelena Djuriš, Mingshi Yang, Sandra Cvijić · 2021 · Asian Journal of Pharmaceutical Sciences
  66. Integration of advanced methods and models to study drug absorption and related processes: An UNGAP perspective
    CLIVE G. WILSON, Leon J Aarons, Patrick Augustijns, Joachim Brouwers, Adam S. Darwich, Tom de Waal, Grzegorz Garbacz, Simone Hansmann, Dagmara Hoc, Anela Ivanova et al. · 2021 · European Journal of Pharmaceutical Sciences
  67. Role of Hepatic Drug Transporters in Drug Development
    Houfu Liu, Jasminder Sahi · 2016 · The Journal of Clinical Pharmacology
  68. Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?
    Ian E. Templeton, Yuan Chen, Jialin Mao, Jian Lin, Hongbin Yu, Solange Peters, Mohamad Shebley, MV Varma · 2016 · CPT Pharmacometrics & Systems Pharmacology
  69. Commentary on the MID3 Good Practices Paper
    Efthymios Manolis, Jacob Brogren, Susan M. Cole, Justin L. Hay, Anna Nordmark, Kristin E. Karlsson, Frederike Lentz, Norbert Benda, Gaby Wangorsch, Gérard Pons et al. · 2017 · CPT Pharmacometrics & Systems Pharmacology
  70. Advancements in Virtual Bioequivalence: A Systematic Review of Computational Methods and Regulatory Perspectives in the Pharmaceutical Industry
    Nasser Alotaiq, Doni Dermawan · 2024 · Pharmaceutics
  71. In Vitro Hepatic Uptake in Human and Monkey Hepatocytes in the Presence and Absence of Serum Protein and Its In Vitro to In Vivo Extrapolation
    Xiaomin Liang, Yeojin Park, Natalie DeForest, Hao Jia, Xiaofeng Zhao, Congrong Niu, Kelly Wang, Bill J. Smith, Yurong Lai · 2020 · Drug Metabolism and Disposition
  72. A permeability‐ and perfusion‐based PBPK model for improved prediction of concentration‐time profiles
    Ken Korzekwa, Casey Radice, Swati Nagar · 2022 · Clinical and Translational Science
  73. Evaluating the performance of machine‐learning regression models for pharmacokinetic drug–drug interactions
    Jaidip Gill, Marie Moullet, Anton Martinsson, Filip N. Miljković, Beth Williamson, Rosalinda H. Arends, Venkatesh Pilla Reddy · 2022 · CPT Pharmacometrics & Systems Pharmacology
  74. A deep neural network: mechanistic hybrid model to predict pharmacokinetics in rat
    Florian Führer, Andrea Grüber, Holger Diedam, Andreas H. Göller, Stephan Menz, Sebastian Schneckener · 2024 · Journal of Computer-Aided Molecular Design
  75. Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations
    Su‐jin Rhee, Hyewon Chung, SoJeong Yi, Kyung‐Sang Yu, Jae‐Yong Chung · 2017 · European Journal of Drug Metabolism and Pharmacokinetics
  76. Development and validation of a physiology-based model for the prediction of pharmacokinetics/toxicokinetics in rabbits
    Panteleimon D. Mavroudis, Helen E. Hermes, Donato Teutonico, Thomas G. Preuß, Sebastian Schneckener · 2018 · PLoS ONE
  77. Impact of Ethnicity-Specific Hepatic Microsomal Scaling Factor, Liver Weight, and Cytochrome P450 (CYP) 1A2 Content on Physiologically Based Prediction of CYP1A2-Mediated Pharmacokinetics in Young and Elderly Chinese Adults
    Guo‐Fu Li, Qingshan Zheng, Yichao Yu, Wei Zhong, Hong‐Hao Zhou, Furong Qiu, Guangji Wang, Guo Yu, Hartmut Derendorf · 2019 · Clinical Pharmacokinetics
  78. Application of New Cellular and Microphysiological Systems to Drug Metabolism Optimization and Their Positioning Respective to In Silico Tools
    Luca Docci, Neil John Parrott, Stephan Krähenbühl, Stephen M. Fowler · 2019 · SLAS DISCOVERY
  79. Physiologically Based Pharmacokinetic Modelling to Investigate the Impact of the Cytokine Storm on CYP3A Drug Pharmacokinetics in COVID‐19 Patients
    Felix Stader, Manuel Battegay, Parham Sendi, Catia Marzolini · 2021 · Clinical Pharmacology & Therapeutics
  80. Physiologically based pharmacokinetic-quantitative systems toxicology and safety (PBPK-QSTS) modeling approach applied to predict the variability of amitriptyline pharmacokinetics and cardiac safety in populations and in individuals
    Zofia Tylutki, Aleksander Mendyk, Sebastian Polak · 2018 · Journal of Pharmacokinetics and Pharmacodynamics
  81. Pharmacokinetic studies in pregnancy
    Michael J. Avram · 2020 · Seminars in Perinatology
  82. Quantitative Estimation of Plasma Free Drug Fraction in Patients With Varying Degrees of Hepatic Impairment: A Methodological Evaluation
    Guo‐Fu Li, Guo Yu, Yanfei Li, Yi Zheng, Qingshan Zheng, Hartmut Derendorf · 2018 · Journal of Pharmaceutical Sciences
  83. In Vitro–In Vivo Extrapolation of OATP1B-Mediated Drug–Drug Interactions in Cynomolgus Monkey
    Ayşe Ufuk, Rachel E. Kosa, Hongying Gao, Yi‐An Bi, Sweta Modi, Dana Gates, A. David Rodrigues, Larry M. Tremaine, Manthena V. S. Varma, James Brian. Houston et al. · 2018 · Journal of Pharmacology and Experimental Therapeutics
  84. Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein
    Shinji Yamazaki, Cho‐Ming Loi, Emi Kimoto, Chester Costales, Manthena V. S. Varma · 2018 · Drug Metabolism and Disposition
  85. A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Model of Dabigatran Etexilate, Dabigatran and Dabigatran Glucuronide in Healthy Adults and Renally Impaired Patients
    Daniel Moj, Hugo J. Maas, André Schaeftlein, Nina Hanke, José David Gómez‐Mantilla, Thorsten Lehr · 2019 · Clinical Pharmacokinetics
  86. A Model-Based Approach To Assessing the Importance of Intracellular Binding Sites in Doxorubicin Disposition
    Ilse R. Dubbelboer, Elsa Lilienberg, Erik Sjögren, Hans Lennernäs · 2017 · Molecular Pharmaceutics
  87. Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism
    Josefine Schulz, Antonia Thomas, Ayatallah Saleh, Gerd Mikus, Charlotte Kloft, Robin Michelet · 2022 · Pharmaceutics
  88. Application of machine learning in combination with mechanistic modeling to predict plasma exposure of small molecules
    Panteleimon D. Mavroudis, Donato Teutonico, Alexandra Abós, Nikhil Pillai · 2023 · Frontiers in Systems Biology
  89. Characterization of Pharmacokinetics in the Göttingen Minipig with Reference Human Drugs: An In Vitro and In Vivo Approach
    Floriane Lignet, Eva Sherbetjian, Nicole A. Kratochwil, Russell Jones, Claudia Suenderhauf, Michael B. Otteneder, Thomas Singer, Neil John Parrott · 2016 · Pharmaceutical Research
  90. Construction and Verification of Physiologically Based Pharmacokinetic Models for Four Drugs Majorly Cleared by Glucuronidation: Lorazepam, Oxazepam, Naloxone, and Zidovudine
    Luca Docci, Kenichi Umehara, Stephan Krähenbühl, Stephen M. Fowler, Neil John Parrott · 2020 · The AAPS Journal
  91. Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4/6 inhibitors: A comprehensive review
    Taha Koray Şahin, Gözde Kavgacı, Deniz Can Güven, Sercan Aksoy · 2025 · Cancer Treatment Reviews
  92. Transporter–enzyme interplay and the hepatic drug clearance: what have we learned so far?
    Ravindra V. Alluri, Rui Li, Manthena V. S. Varma · 2020 · Expert Opinion on Drug Metabolism & Toxicology
  93. Use of Antibiotics in Preterm Newborns
    Raffaele Simeoli, Sara Cairoli, Nunzia Decembrino, Francesca Campi, Carlo Dionisi‐Vici, Alberto Corona, Bianca Maria Goffredo · 2022 · Antibiotics
  94. Shared learning from a physiologically based pharmacokinetic modeling strategy for human pharmacokinetics prediction through retrospective analysis of Genentech compounds
    Jialin Mao, Fang Ma, Jesse Yu, Tom De Bruyn, Miaoran Ning, Christine M. Bowman, Yuan Chen · 2023 · Biopharmaceutics & Drug Disposition
  95. Binding of dicoumarol analog with DNA and its antioxidant studies: A biophysical insight by in-vitro and in-silico approaches
    Kandikonda Lavanya, Pratap Veeresh Babu, Anna Tanuja Safala Bodapati, Ragaiahgari Srinivas Reddy, Shravya Rao Madku, Bijaya Ketan Sahoo · 2023 · International Journal of Biological Macromolecules
  96. Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug–Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype
    Manting Chiang, Caroline J. Sychterz, Vidya Perera, Samira J. Merali, Maria Palmisano, Ian E. Templeton, Lu Gaohua · 2023 · Clinical Pharmacology & Therapeutics
  97. Baricitinib and tofacitinib off‐target profile, with a focus on Alzheimer's disease
    Maria Luisa Faquetti, Laura Slappendel, Hélène Bigonne, Francesca Grisoni, Petra Schneider, Georg Aichinger, Gisbert Schneider, Shana J. Sturla, Andrea Michelle Burden · 2024 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  98. Medicines for Pediatric Patients—Biopharmaceutical, Developmental, and Regulatory Considerations
    David P. Elder, René Holm, Martin Kuentz · 2016 · Journal of Pharmaceutical Sciences
  99. Hepatic Organic Anion Transporting Polypeptide–Mediated Clearance in the Beagle Dog: Assessing In Vitro–In Vivo Relationships and Applying Cross-Species Empirical Scaling Factors to Improve Prediction of Human Clearance
    Norikazu Matsunaga, Ayşe Ufuk, Bridget L. Morse, David W. Bedwell, Jingqi Bao, Michael A. Mohutsky, Kathleen M. Hillgren, Stephen David Hall, James Brian. Houston, Aleksandra Galetin · 2018 · Drug Metabolism and Disposition
  100. The Segregated Intestinal Flow Model (SFM) for Drug Absorption and Drug Metabolism: Implications on Intestinal and Liver Metabolism and Drug–Drug Interactions
    K. Sandy Pang, Hao Peng, Keumhan Noh · 2020 · Pharmaceutics